Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503
AGENCY USE ONLY (Leave blank)
REPORT DATE
October 1999
REPORT TYPE AND DATES COVERED
Final (16 Sep 94 -15 Sep 99)
TITLE AND SUBTITLE
Non-Invasive Detection of Axillary Nodes by Contrast Enhanced Magnetic Resonance Imaging
AUTHOR(S)Jason Koutcher, M.D., Ph.D. koutchej@mskcc.org Previous studies in murine tumors have shown that the 3 drug combination of PALA + MMPR + 6AN (PMA) [PALA (n-phosphonacetyl aspartate), MMPR (6-methylmercaptopurine riboside), 6AN (6-aminonicotinamide); referred to as PMA] is an effective radiation (XRT) sensitizer. Using the MCF-7 human mammary tumor, we detected 6-phosphogluconate (6PG), an intermediate in the pentose phosphate pathway, and a reduction in nucleoside triphosphates after treatment with PMA in vivo, hi vivo studies indicated that PMA induces a tumor response as evidenced by an increase in tumor growth delay from 10.2 +/-4.6 (control) to 29.3 +/-6.7 days. Neither PMA nor XRT alone induced tumor shrinkage. PMA-> 5 Gy induced tumor shrinkage and after 33 days the tumors had not attained their pretreatment volume. By day 51, the mice still had not doubled their tumor volume, indicating that PMA is an active regimen in human tumors, and an effective XRT sensitizer. We also investigated the efficacy of combining with paclitaxel with bryostatin. Bryostatin 1, if administered first, decreased the efficacy of paclitaxel but if administered after paclitaxel moderately enhanced (p<0.05) tumor growth delay compared to paclitaxel alone. Further studies suggested that this could be due to changes in pH, blood flow, or cells traversing mitosis. Previous studies by this investigator have shown that PMA[PALA + MMPR + 6AN [PALA (nphosphonacetyl aspartate), MMPR (6-methylmercaptopurine riboside), 6AN (6-aminonicotinamide); referred to as PMA] is an effective radiosensitizer and enhances chemotherapy in two tumor models (1-5). In addition, we have shown that 6AN enhances the effect of radiation on RIF-1 fibrosarcoma cells (6,7). This enhancement has been shown to be sequence dependent, i.e. if the radiation is administered prior to 6AN there is no enhancement. A criticism of the study that has been done was that the study was done in murine tumors; the NIH has suggested that human tumors need to be studied. Thus the goal of the current studies are to 1. Determine if 6 AN enhances the effects of radiation in ...